Document Detail

Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study.
MedLine Citation:
PMID:  16929547     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Many women take non-steroidal anti-inflammatory drugs (NSAIDs) during pregnancy but the risks for the infant remain controversial. We carried out a study to quantify the association between those women prescribed NSAIDs in early pregnancy and congenital anomalies. METHODS: A population-based pregnancy registry was built by linking data from three administrative databases in Quebec between 1997-2003. The inclusion criteria were mothers of live singleton infants, between 15-45 years of age, covered by the RAMQ drug plan > or =12 months before and during pregnancy, and prescribed an NSAID or other medications during pregnancy. We selected as cases infants with any congenital anomaly (ICD-9; 740-759) diagnosed in the first year of life. Up to 10 controls, defined as infants with no congenital anomalies detected were selected for each case. Adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated. RESULTS: Within the registry, 36,387 pregnant women met the inclusion criteria. We identified 93 births with congenital anomalies in 1056 women (8.8%) who filled prescriptions for NSAIDs in the first trimester of pregnancy, compared to 2478 in 35,331 (7%) women who did not. The adjusted OR for any congenital anomalies for women who filled a prescription for NSAIDs in the first trimester was 2.21 (95% CI = 1.72-2.85). The adjusted OR for the anomalies related to cardiac septal closure was 3.34 (95% CI = 1.87-5.98). There were no significant associations with anomalies of other major organ systems. CONCLUSIONS: Our study suggests that women prescribed NSAIDs during early pregnancy may be at a greater risk of having children with congenital anomalies, specifically cardiac septal defects.
Benjamin Ofori; Driss Oraichi; Lucie Blais; Evelyne Rey; Anick Bérard
Related Documents :
24380787 - Supplementary corpora lutea monitoring allows progestin treatment interruption on day 7...
16837097 - Maternal third trimester hyperglycaemic excursions predict large-for-gestational-age in...
16260517 - Risk factors for spontaneous abortion in early symptomatic first-trimester pregnancies.
6743577 - Exposure to solvents and outcome of pregnancy in university laboratory employees.
11132387 - Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morb...
6159997 - Concanavalin a reactivity pattern of human amniotic fluid afp examined by crossed affin...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Birth defects research. Part B, Developmental and reproductive toxicology     Volume:  77     ISSN:  1542-9733     ISO Abbreviation:  Birth Defects Res. B Dev. Reprod. Toxicol.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-10-02     Completed Date:  2006-10-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101155115     Medline TA:  Birth Defects Res B Dev Reprod Toxicol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  268-79     Citation Subset:  IM    
Copyright Information:
Copyright 2006 Wiley-Liss, Inc.
Research Center, Sainte-Justine Hospital, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Drug-Induced*
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
Case-Control Studies
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Motor neuron disease associated with copper deficiency.
Next Document:  Testing effective connectivity changes with structural equation modeling: what does a bad model tell...